Brief: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential For Differentiated Safety And Efficacy In Patients With PIK3CA-Driven Vascular Anomalies
19/05/2026 11:02
May 19 (Reuters) - Relay Therapeutics Inc RLAY.O: RELAY THERAPEUTICS ANNOUNCES INITIAL CLINICAL DATA DEMONSTRATING THAT ZOVEGALISIB HAS POTENTIAL FOR DIFFERENTIATED SAFETY AND EFFICACY IN PATIENTS WITH PIK3CA-DRIVEN VASCULAR ANOMALIES RELAY THERAPEUTICS INC - NO PATIENTS DISCONTINUED TREATMENT DUE TO ADVERSE EVENTS RELAY THERAPEUTICS INC - 89% INVESTIGATOR-REPORTED AND 79% PATIENT-REPORTED CLINICAL IMPROVEMENT AT WEEK 12 RELAY THERAPEUTICS INC - 60% OF PATIENTS ACHIEVE VOLUMETRIC RESPONSE AT 12 WEEKS AS OF APRIL 15, 2026 Source text: ID:nGNXMJmdL Further company coverage: RLAY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relay Therapeutics
See all newsBrief: X-Chem Announces Phase 3 Milestone In Collaboration With Relay Therapeutics
Relay Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Relay Therapeutics Q2 revenue misses estimates on higher R&D expenses; net loss widens
Brief: Relay Therapeutics Q2 Net Income USD -83.707 Million Vs. IBES Estimate USD -74.2 Million
U.S. RESEARCH ROUNDUP- Alliant Energy, Prog Holdings, Travelers